NDLI: Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.

Please wait, while we are loading the content...

Relevance of the POS-1 orthotopic model as an 'imaging model' for in vivo and simultaneous monitoring of tumor proliferation and bone remodeling in osteosarcoma.

Progress in cancer therapy.

Improving radioresponse through modification of the tumor immunological microenvironment.

Predictors of Long-Term Outcome from Intraperitoneal Radioimmunotherapy for Ovarian Cancer

Antitumor effect of a generation 4 polyamidoamine dendrimer/cyclooxygenase-2 antisense oligodeoxynucleotide complex on breast cancer in vitro and in vivo.

Down-regulation of survivin and hypoxia-inducible factor-1 by ß-elemene enhances the radiosensitivity of lung adenocarcinoma xenograft.

Recent advances in therapeutic cancer vaccines.

Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation.

Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.

Year: 2011 Volume: 26

Year: 2010 Volume: 25

Year: 2009 Volume: 24

Year: 2008 Volume: 23

Year: 2007 Volume: 22

Year: 2006 Volume: 21

Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Gameiro, Sofia R. Caballero, Jorge A. Hodge, James W.
Description	Country affiliation: United States Author Affiliation: Gameiro SR ( Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.)
Abstract	Chemotherapy with platinum doublets, including cisplatin plus vinorelbine, is standard of care for non-small-cell lung cancer. Sublethal exposure to certain chemotherapeutic agents has been demonstrated to alter the phenotype or biology of human tumor cells, rendering them more susceptible to cytotoxic T lymphocyte (CTL)-mediated lysis. The effects of cisplatin/vinorelbine on tumor sensitivity to T-cell cytotoxicity and its molecular mechanisms, however, have not been fully elucidated. We examined the effect of this chemotherapy on growth, cell-surface phenotype, and CTL-mediated lysis of five distinct human lung carcinoma cell lines in vitro and examined the molecular mechanisms associated with enhanced CTL sensitivity. These studies demonstrate that sublethal exposure of human lung tumor cells to the platinum doublet modulates tumor cell phenotype and increases sensitivity to major histocompatibility complex-restricted perforin/granzyme-mediated CTL killing. These studies also demonstrate that exposure to chemotherapy markedly decreased the protein secretion ratio of transforming growth factor-ß/interleukin (IL)-8. We examined the gene expression profile of two lung tumor cell lines to identify a shared gene signature in response to sublethal cisplatin/vinorelbine and found coordinate expression of only 16 transcripts, including those for cytokine/chemokine expression and apoptosis such as tumor necrosis factor- , IL8, CXCL5, and B cell lymphoma-2-like genes (BCL-2). Overall, these results suggest that sublethal exposure to cisplatin/vinorelbine increases sensitivity to perforin/granzyme-mediated CTL killing by modulation of (a) tumor phenotype, (b) cytokine/chemokine milieu, and (c) the proapoptotic/antiapoptotic gene ratio. The data presented here propose a complex mechanism that is distinct from and complementary to that of immunogenic cell death. This molecular signature may be useful in predicting responses to immunotherapy as well as provide the rationale for the potential clinical benefit of the combined use of vaccine with cisplatin/vinorelbine regimens.
File Format	HTM / HTML
ISSN	10849785
e-ISSN	15578852
DOI	10.1089/cbr.2012.1203
Journal	Cancer Biotherapy & Radiopharmaceuticals
Issue Number	1
Volume Number	27
Language	English
Publisher	Mary Ann Liebert, Inc.
Publisher Date	2012-02-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Pharmacology Discipline Oncology Antineoplastic Combined Chemotherapy Protocols Pharmacology Carcinoma, Non-small-cell Lung Therapy Immunotherapy, Adoptive Lung Neoplasms T-lymphocytes, Cytotoxic Drug Effects Immunology Apoptosis Drug Therapy Cell Line, Tumor Cisplatin Administration & Dosage Combined Modality Therapy Microarray Analysis T-lymphocytes Tumor Cells, Cultured Vinblastine Analogs & Derivatives Research Support, N.i.h., Intramural
Content Type	Text
Resource Type	Article
Subject	Radiology, Nuclear Medicine and Imaging Cancer Research Pharmacology Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

A retrospective study of concurrent chemoradiation using mitomycin, vinblastine and cisplatin chemotherapy for non-small cell lung cancer.

Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes.

Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma.

Chemotherapy in lung cancer.

Defining the Molecular Signature of Chemotherapy-Mediated Lung Tumor Phenotype Modulation and Increased Susceptibility to T-Cell Killing

Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

Analysis of a novel protocol of combined induction chemotherapy and concurrent chemoradiation in unresected non-small-cell lung cancer: a ten-year experience with vinblastine, Cisplatin, and radiation therapy.

Immunotherapy for Advanced Lung Cancer.

Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.

Similar Documents

A retrospective study of concurrent chemoradiation using mitomycin, vinblastine and cisplatin chemotherapy for non-small cell lung cancer.

Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes.

Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma.

Chemotherapy in lung cancer.

Defining the Molecular Signature of Chemotherapy-Mediated Lung Tumor Phenotype Modulation and Increased Susceptibility to T-Cell Killing

Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

Analysis of a novel protocol of combined induction chemotherapy and concurrent chemoradiation in unresected non-small-cell lung cancer: a ten-year experience with vinblastine, Cisplatin, and radiation therapy.

Immunotherapy for Advanced Lung Cancer.

Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.